AZD7003
Cell therapy
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
No clinical trials on ClinicalTrials.gov
No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
This drug's own stage for Hepatocellular Carcinoma: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| AZD7003: this drug | Stage not on record | Cell therapy | Glypican-3 (GPC3) | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Approved | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | Partial signal | NCT01908426: Overall Survival (OS) (Up to 45 months): Cabozantinib (XL184) 10.2 months (95% CI 9.1 to 12) | Placebo 8 months (95% CI 6.8 to 9.4) | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT03062358: Overall Survival (OS) (Up to approximately 4 years): Pembrolizumab + BSC 14.6 Months (95% CI 12.6 to 18) | Placebo + BSC 13 Months (95% CI 10.5 to 15.1) | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Partial signal | NCT02435433: Overall Survival (OS) (From Date of Randomization to Death from Any Cause (Up to 28 Months)): Ramucirumab + Best Supportive Care (BSC) 8.51 Months (95% CI 7 to 10.58) | Placebo + BSC 7.29 Months (95% CI 5.42 to 9.07) | |
| Regorafenib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | not yet graded | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tremelimumab | Approved | Monoclonal antibody | CTLA-4 | Partial signal | No reviewed efficacy summary in this indication | |
| Amezalpat | Phase 3 | Small molecule | PPARα (peroxisome proliferator-activated receptor alpha) | not yet graded | No reviewed efficacy summary in this indication | |
| Apatinib | Phase 3 | Small molecule | VEGFR2 | not yet graded | No reviewed efficacy summary in this indication | |
| BGB-B2033 | Phase 3 | Multispecific antibody | GPC3 (glypican-3) x 4-1BB (CD137) | not yet graded | No reviewed efficacy summary in this indication | |
| Cadonilimab | Phase 3 | Multispecific antibody | PD-1×CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| JS207 | Phase 3 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Namodenoson | Phase 3 | — | Adenosine A3 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Nilvanstomig | Phase 3 | Biologic (subtype unspecified) | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Pegargiminase | Phase 3 | Protein / enzyme therapeutic | Arginine-depleting pegylated arginine deiminase | not yet graded | No reviewed efficacy summary in this indication | |
| Penpulimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| RYZ801 | Phase 1/2 | Radiopharmaceutical | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-324 | Phase 1 | Antibody–drug conjugate | Glypican-3 (GPC3) / Topoisomerase I | not yet graded | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| SENTI-301A | Phase 1 | Cell therapy | GPC3 (CAR-NK, calibrated IL-15) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2524 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.